![]() | This article is rated Stub-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||
|
![]() | This edit request by an editor with a conflict of interest has now been answered. |
SarahB53 ( talk) 15:06, 29 August 2023 (UTC)
References
Implemented
Spintendo
01:22, 30 August 2023 (UTC)
" I'd like to point out that Mikael Dolsten's new role is "Chief Scientific Officer, President, Pfizer Research & Development" (copied from MM+M - Medical Marketing and Media). "Chief Oncology Research and Development Officer and EVP" is Chris Boshoff's new title, not Mikael's."is not encyclopedic, and cannot be added in that manner.
Sample edit request
|
---|
|
Regards,
Spintendo
23:13, 7 September 2023 (UTC)
References
Instructions for Submitters: Describe the requested changes in detail. This includes the exact proposed wording of the new material, the exact proposed location for it, and an explicit description of any wording to be removed, including removal for any substitution.
Instructions for Submitters: If the rationale for a change is not obvious (particularly for proposed deletions), explain.
![]() | This edit request by an editor with a conflict of interest has now been answered. |
SarahB53 ( talk) 19:04, 6 September 2023 (UTC)
References
![]() | This edit request by an editor with a conflict of interest has now been answered. |
“Mikael Dolsten (born c. 1958) is a Swedish-American physician scientist, and the President of research & development-Medical (chief scientific officer) of the American Pharmaceutical company Pfizer. ”
“Mikael Dolsten (born c. 1958) is a Swedish-American physician scientist, and the Chief Scientific Officer and the President of Pfizer Research & Development of the American Pharmaceutical company Pfizer. ”
Masson, G. (2023, July 28). Chutes & Ladders-Pfizer exec out the door in R&D shake-up. Fierce Biotech. https://www.fiercebiotech.com/biotech/chutes-ladders-pfizer-exec-out-door-rd-shake [1] :
“To reflect his current position and title.”
SarahB53 (
talk)
21:16, 8 September 2023 (UTC)
References
Already done This title is already reflected in the lead. Changing the word sequence preference is merely window dressing. Regards,
Spintendo
22:22, 10 September 2023 (UTC)
![]() | This edit request by an editor with a conflict of interest has now been answered. |
“This company would be bought by Pfizer in 1997.” :
“Pfizer agreed to acquire Pharmacia in 2002 and the merger closed in 2003.” :
Politico. (2002, July 24). PHARMACEUTICAL – Pfizer buys Pharmacia. Politico. https://www.politico.eu/article/pharmaceutical-pfizer-buys-pharmacia/
CNN Money. (2003, April 16). It’s official: Pfizer buys Pharmacia. CNN Money. https://money.cnn.com/2003/04/16/news/companies/pfizer_pharma/: :
To reflect the accurate information. :
SarahB53 ( talk) 21:57, 25 September 2023 (UTC)
References
Done IMHO the COI editor should focus on adding more substantial secondary-source references to the article, rather than window-dressing type changes. Those types of improved references (including adding references to substantial information which is unreferenced) would benefit the article greatly.
Spintendo
20:23, 26 September 2023 (UTC)
![]() | This edit request by an editor with a conflict of interest was declined. The reviewer has asked the COI editor to make changes and/or clarifications to the proposed text before the request is reviewed. |
Early Life section
“He is Jewish.”
“He pursued scientific studies in immunology and virology 1981 at the Weizmann Institute of Science in Rehovot Israel.”
Career: Pharmacia section
“Dolsten worked from 1988 to 1997 for the Swedish company Pharmacia in Lund. The last few years in this period he served as head of research for the Lund research center working in immune and cancer therapeutics.”
SarahB53 ( talk) 19:31, 1 November 2023 (UTC)
References
He is Jewishappears, on its own, not to be very encyclopedic in its prosaic appearance, no matter how genuine and accurate the statement appears to be. I would suggest placing the phrase within another sentence — either newly proposed or perhaps an existing one already in the article — so that its appearance in the text to the reader as only 3 words is not so abrupt.
He pursued scientific studies in immunology and virology 1981 at the Weizmann Institute of Science in Rehovot Israelit is not clear what is meant by the phrase "he pursued". Needless to say, the pursuit of studies in most countries entails pursuit of a degree of some sort. This sentence would benefit from an elaboration of that kind. Please advise.
Regards, Spintendo 00:34, 2 November 2023 (UTC)
![]() | This edit request by an editor with a conflict of interest has now been answered. |
Early Life Section
+++
+++
Career Section - Pharmacia
SarahB53 ( talk) 18:55, 16 November 2023 (UTC)
References
Approved
Spintendo
01:16, 17 November 2023 (UTC)
![]() | This edit request by an editor with a conflict of interest has now been answered. |
Can you update the AstraZeneca section into two sections (AstraZeneca and Boehringer Ingleheim) as below?
AstraZeneca
From 1997 to 2003, he worked for the Swedish pharmaceutical company Astra AB, which later merged with the British company Zeneca and became AstraZeneca, [1] as head of research. [2]
Boehringer Ingelheim
Dolsten served as Executive Vice President, Pharma Research for Boehringer Ingelheim [3] and then relocated to their U.S. office. [4]
+++
Can you update the first paragraph of the Pfizer section as below?
Pfizer
Dolsten led Wyeth’s Research and Development [5] and after the close of the Wyeth acquisition in 2009, [6] he was named President of Pfizer’s BioTherapeutics Research & Development. [7] He became the global chief of Pfizer research and development in May 2010, replacing Martin Mackay. [8] In July 2023, his role expanded to Chief Scientific Officer, President, Pfizer Research & Development to lead all discovery, early- and late-stage clinical development, for all non-oncology therapeutic areas. [9]
+++
References
1. DePalma, A. (1998, December 9). “ Astra, Zeneca to Merge”. Pharmaceutical Online. Retrieved 15 December 2023. Pharmaceutical Online has 32,957 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.
2. “ IVAs Guldmedalj 2021: Mikael Dolsten”. IVA. 20 March 2023. Retrieved 15 December 2023. The Royal Swedish Academy of Engineering Sciences (IVA) has 7,498 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.
3. “ Boehringer and Yale Combine Strengths in New Research Alliance”. Yale Medicine. March-April 2006. Retrieved 15 December 2023. Yale Medicine has 1,505,273 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.
4. Friedman, G. (17 November 2020). “ Mikael Dolsten, Jewish Immigrant and Top Pfizer Scientist, Hails US Melting Pot”. The Times of Israel. Retrieved 15 December 2023. The Times of Israel has 24,028,472 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.
5. Friedman, G. (16 November 2020). “ Mikael Dolsten, the Jewish Immigrant Leading Pfizer’s Vaccine Charge, Hopes the US Stays a Melting Pot”. Jewish Telegraphic Agency. Retrieved 15 December 2023. The Times of Israel has 771,950 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.
6. “ Pfizer Completes $67 Billion Deal for Rival Wyeth”. Reuters. 15 October 2009. Retrieved 13 December 2023. Reuters has 54,756,032 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.
7. Taylor, N. (1 June 2010). “ Pfizer and AstraZeneca naming R&D Leaders and Appointments at APV and Lonza – People on the Move”. Outsourcing Pharma. Retrieved 15 December 2023. Outsourcing Pharma has 31,781 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.
8. Carroll, J. (26 May 2010). “ Mackay Moves to AZ as Dolsten Takes Pfizer’s R&D Crown”. Fierce Biotech. Retrieved 15 December 2023. Fierece Biotech has 506,921 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.
9. O’Brien, J. (27 July 2023). “ Pfizer Elevates Chris Boshoff to Head R&D in Organizational Shakeup”. MM+M. Retrieved 13 December 2023. MM+M has 48,064 Unique Monthly Visitors (data obtained via Similarweb) and is a noteworthy secondary source.
+++
SarahB53 ( talk) 21:38, 15 December 2023 (UTC)
References
I've omitted the different headings of the pharm companies because the information within them was of a size that is too small to justify having separate headings. The information on the subject's varying activities at Pfizer were not added, suffice it to say, that the subject worked at Pfizer is enough to state. The different activities they performed are not germane to the whole of the article, as this is WP:NOTRESUME. Regards, Spintendo 00:25, 19 December 2023 (UTC)